Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
- Author:
Hsu-Heng YEN
1
;
Jia-Feng WU
;
Horng-Yuan WANG
;
Ting-An CHANG
;
Chung-Hsin CHANG
;
Chen-Wang CHANG
;
Te-Hsin CHAO
;
Jen-Wei CHOU
;
Yenn-Hwei CHOU
;
Chiao-Hsiung CHUANG
;
Wen-Hung HSU
;
Tzu-Chi HSU
;
Tien-Yu HUANG
;
Tsung-I HUNG
;
Puo-Hsien LE
;
Chun-Che LIN
;
Chun-Chi LIN
;
Ching-Pin LIN
;
Jen-Kou LIN
;
Wei-Chen LIN
;
Yen-Hsuan NI
;
Ming-Jium SHIEH
;
I-Lun SHIH
;
Chia-Tung SHUN
;
Tzung-Jiun TSAI
;
Cheng-Yi WANG
;
Meng-Tzu WENG
;
Jau-Min WONG
;
Deng-Chyang WU
;
Shu-Chen WEI
Author Information
- Publication Type:Statement
- From:Intestinal Research 2024;22(3):213-249
- CountryRepublic of Korea
- Language:EN
- Abstract: Ulcerative colitis (UC) is a chronic inflammation of the gastrointestinal tract and is characterized by alternating periods of inflammation and remission. Although UC incidence is lower in Taiwan than in Western countries, its impact remains considerable, demanding updated guidelines for addressing local healthcare challenges and patient needs. The revised guidelines employ international standards and recent research, emphasizing practical implementation within the Taiwanese healthcare system. Since the inception of the guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease has acknowledged the need for ongoing revisions to incorporate emerging therapeutic options and evolving disease management practices. This updated guideline aims to align UC management with local contexts, ensuring comprehensive and context-specific recommendations, thereby raising the standard of care for UC patients in Taiwan. By adapting and optimizing international protocols for local relevance, these efforts seek to enhance health outcomes for patients with UC.
